SubHero Banner

molnupiravir – Emergency use authorization

December 23, 2021 - The FDA announced the emergency use authorization (EUA) approval of Merck’s molnupiravir, for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing who are at high risk for progressing to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate.

Download PDF